Shares of Celsion Corporation (NASDAQ:CLSN) shot up 0% on Friday . The stock traded as high as $2.09 and last traded at $2.00. 2,286,596 shares traded hands during trading, an increase of 63% from the average session volume of 1,401,962 shares. The stock had previously closed at $2.00.

Several research firms have weighed in on CLSN. Zacks Investment Research downgraded Celsion Corporation from a “buy” rating to a “hold” rating in a research note on Tuesday, October 17th. Maxim Group upgraded Celsion Corporation from a “hold” rating to a “buy” rating and set a $7.00 price target on the stock in a research note on Wednesday, October 4th. Finally, ValuEngine upgraded Celsion Corporation from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $12.63.

An institutional investor recently bought a new position in Celsion Corporation stock. Sabby Management LLC bought a new position in Celsion Corporation (NASDAQ:CLSN) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 108,843 shares of the biotechnology company’s stock, valued at approximately $223,000. Sabby Management LLC owned about 1.30% of Celsion Corporation as of its most recent SEC filing. 5.66% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: “Celsion Corporation (CLSN) Shares Up 0%” was originally published by Watch List News and is the property of of Watch List News. If you are viewing this news story on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The legal version of this news story can be accessed at

Celsion Corporation Company Profile

Celsion Corporation is an oncology drug development company. The Company’s product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study).

Receive News & Ratings for Celsion Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.